Sepsis Drug Risks
Abstract
Reports of serious bleeding and deaths among patients treated for severe sepsis with a recombinant form of human activated protein C, drotrecogin alfa, have prompted the US Food and Drug Administration (FDA) to evaluate these safety concerns, according to an early communication from the agency. According to the FDA, after a recent retrospective study suggested that patients with severe sepsis and certain concurrent risk factors for bleeding may be more likely than patients without such risk...